Joseph M Collaco1, Scott M Blackman1, Karen S Raraigh1, Harriet Corvol2,3, Johanna M Rommens4, Rhonda G Pace5, Pierre-Yves Boelle3,6,7, John McGready8, Patrick R Sosnay1, Lisa J Strug4, Michael R Knowles5, Garry R Cutting1. 1. 1 School of Medicine and. 2. 2 Assistance Publique-Hôpitaux de Paris, Trousseau Hospital, Paris, France. 3. 3 Institut National de la Santé et la Recherche Médicale, Paris, France. 4. 4 The Hospital for Sick Children and the University of Toronto, Toronto, Canada. 5. 5 Marsico Lung Institute/Cystic Fibrosis and Pulmonary Diseases Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 6. 6 Sorbonne Universités, Université Pierre et Marie Curie, Paris, France; and. 7. 7 Assistance Publique-Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France. 8. 8 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Abstract
RATIONALE: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators and correctors for the treatment of cystic fibrosis (CF) requires precise and accurate biomarkers. Sweat chloride concentration provides an in vivo assessment of CFTR function, but it is unknown the degree to which CFTR mutations account for sweat chloride variation. OBJECTIVES: To estimate potential sources of variation for sweat chloride measurements, including demographic factors, testing variability, recording biases, and CFTR genotype itself. METHODS: A total of 2,639 sweat chloride measurements were obtained in 1,761 twins/siblings from the CF Twin-Sibling Study, French CF Modifier Gene Study, and Canadian Consortium for Genetic Studies. Variance component estimation was performed by nested mixed modeling. MEASUREMENTS AND MAIN RESULTS: Across the tested CF population as a whole, CFTR gene mutations were found to be the primary determinant of sweat chloride variability (56.1% of variation) with contributions from variation over time (e.g., factors related to testing on different days; 13.8%), environmental factors (e.g., climate, family diet; 13.5%), other residual factors (e.g., test variability; 9.9%), and unique individual factors (e.g., modifier genes, unique exposures; 6.8%) (likelihood ratio test, P < 0.001). Twin analysis suggested that modifier genes did not play a significant role because the heritability estimate was negligible (H2 = 0; 95% confidence interval, 0.0-0.35). For an individual with CF, variation in sweat chloride was primarily caused by variation over time (58.1%) with the remainder attributable to residual/random factors (41.9%). CONCLUSIONS: Variation in the CFTR gene is the predominant cause of sweat chloride variation; most of the non-CFTR variation is caused by testing variability and unique environmental factors. If test precision and accuracy can be improved, sweat chloride measurement could be a valuable biomarker for assessing response to therapies directed at mutant CFTR.
RATIONALE: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators and correctors for the treatment of cystic fibrosis (CF) requires precise and accurate biomarkers. Sweat chloride concentration provides an in vivo assessment of CFTR function, but it is unknown the degree to which CFTR mutations account for sweat chloride variation. OBJECTIVES: To estimate potential sources of variation for sweat chloride measurements, including demographic factors, testing variability, recording biases, and CFTR genotype itself. METHODS: A total of 2,639 sweat chloride measurements were obtained in 1,761 twins/siblings from the CF Twin-Sibling Study, French CF Modifier Gene Study, and Canadian Consortium for Genetic Studies. Variance component estimation was performed by nested mixed modeling. MEASUREMENTS AND MAIN RESULTS: Across the tested CF population as a whole, CFTR gene mutations were found to be the primary determinant of sweat chloride variability (56.1% of variation) with contributions from variation over time (e.g., factors related to testing on different days; 13.8%), environmental factors (e.g., climate, family diet; 13.5%), other residual factors (e.g., test variability; 9.9%), and unique individual factors (e.g., modifier genes, unique exposures; 6.8%) (likelihood ratio test, P < 0.001). Twin analysis suggested that modifier genes did not play a significant role because the heritability estimate was negligible (H2 = 0; 95% confidence interval, 0.0-0.35). For an individual with CF, variation in sweat chloride was primarily caused by variation over time (58.1%) with the remainder attributable to residual/random factors (41.9%). CONCLUSIONS: Variation in the CFTR gene is the predominant cause of sweat chloride variation; most of the non-CFTR variation is caused by testing variability and unique environmental factors. If test precision and accuracy can be improved, sweat chloride measurement could be a valuable biomarker for assessing response to therapies directed at mutant CFTR.
Authors: M P Anderson; R J Gregory; S Thompson; D W Souza; S Paul; R C Mulligan; A E Smith; M J Welsh Journal: Science Date: 1991-07-12 Impact factor: 47.728
Authors: Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle Journal: N Engl J Med Date: 2015-05-17 Impact factor: 91.245
Authors: Michael P Boyle; Scott C Bell; Michael W Konstan; Susanna A McColley; Steven M Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish R Patel; David Rodman Journal: Lancet Respir Med Date: 2014-06-24 Impact factor: 30.700
Authors: Frauke Stanke; Tim Becker; Vinod Kumar; Silke Hedtfeld; Christian Becker; Harry Cuppens; Stephanie Tamm; Jennifer Yarden; Ulrike Laabs; Benny Siebert; Luis Fernandez; Milan Macek; Dragica Radojkovic; Manfred Ballmann; Joachim Greipel; Jean-Jacques Cassiman; Thomas F Wienker; Burkhard Tümmler Journal: J Med Genet Date: 2010-09-12 Impact factor: 6.318
Authors: Fred A Wright; Lisa J Strug; Vishal K Doshi; Clayton W Commander; Scott M Blackman; Lei Sun; Yves Berthiaume; David Cutler; Andreea Cojocaru; J Michael Collaco; Mary Corey; Ruslan Dorfman; Katrina Goddard; Deanna Green; Jack W Kent; Ethan M Lange; Seunggeun Lee; Weili Li; Jingchun Luo; Gregory M Mayhew; Kathleen M Naughton; Rhonda G Pace; Peter Paré; Johanna M Rommens; Andrew Sandford; Jaclyn R Stonebraker; Wei Sun; Chelsea Taylor; Lori L Vanscoy; Fei Zou; John Blangero; Julian Zielenski; Wanda K O'Neal; Mitchell L Drumm; Peter R Durie; Michael R Knowles; Garry R Cutting Journal: Nat Genet Date: 2011-05-22 Impact factor: 38.330
Authors: Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting Journal: Am J Respir Crit Care Med Date: 2019-05-01 Impact factor: 21.405
Authors: Edith T Zemanick; Michael W Konstan; Donald R VanDevanter; Steven M Rowe; J P Clancy; Katherine Odem-Davis; Michelle Skalland; Nicole Mayer-Hamblett Journal: J Cyst Fibros Date: 2021-02-08 Impact factor: 5.482
Authors: Briana Vecchio-Pagán; Scott M Blackman; Melissa Lee; Melis Atalar; Matthew J Pellicore; Rhonda G Pace; Arianna L Franca; Karen S Raraigh; Neeraj Sharma; Michael R Knowles; Garry R Cutting Journal: Hum Genome Var Date: 2016-11-24
Authors: Tyler R Ray; Maja Ivanovic; Paul M Curtis; Daniel Franklin; Kerem Guventurk; William J Jeang; Joseph Chafetz; Hannah Gaertner; Grace Young; Steve Rebollo; Jeffrey B Model; Stephen P Lee; John Ciraldo; Jonathan T Reeder; Aurélie Hourlier-Fargette; Amay J Bandodkar; Jungil Choi; Alexander J Aranyosi; Roozbeh Ghaffari; Susanna A McColley; Shannon Haymond; John A Rogers Journal: Sci Transl Med Date: 2021-03-31 Impact factor: 17.956